Eli Lilly and Company in the news

Eli Lilly reported strong Q2 2026 earnings with robust revenue growth from key products, raised full-year guidance, achieved multiple regulatory milestones, and strategically expanded its pipeline through acquisitions.

Eli Lilly's stock has shown substantial growth over the past decade, driven by its diversified product portfolio and strategic acquisitions in various therapeutic areas.

Eli Lilly's strong demand for diabetes and weight-loss therapies is generating substantial cash flow, which is reinvested into a broad pipeline across oncology, neuroscience, immunology, and mental health, positioning it as a compelling long-term investment.

Eli Lilly, a pharma giant, achieved a $1 trillion market cap last year driven by its GLP-1 drugs, leading to significant investments in biotech acquisitions and global collaborations.

Eli Lilly and Company is facing multiple lawsuits alleging that its diabetes and weight-loss drugs Mounjaro and Trulicity caused severe stomach problems, including gastroparesis, due to inadequate warnings.

Eli Lilly is expanding its Alzheimer's drug pipeline with a new Phase 1 clinical trial for LY4560736 to evaluate its early safety and brain exposure.

Eli Lilly is building a dominant obesity and diabetes treatment portfolio, driven by Mounjaro and Zepbound, leading to high revenue growth and a premium valuation.

Eli Lilly's Q2/26 results showed significant revenue growth, driven largely by Mounjaro and Zepbound, but its high valuation and reliance on these two drugs raise concerns about its future growth and stock price.

Eli Lilly partnered with Ginkgo Bioworks to leverage AI for drug discovery, causing Ginkgo's stock to double, despite its history of inconsistent financial performance and high risk.

Eli Lilly and Novo Nordisk are in a fierce competition for market dominance in weight-loss and diabetes treatments, with Eli Lilly showing rapid growth and higher profitability, and Novo Nordisk offering a strong dividend and lower valuation.

Eli Lilly's stock, while benefiting from successful GLP-1 drugs, faces risks due to its high valuation and increasing competition in the growing GLP-1 market.

Eli Lilly's experimental cancer drug, Olomorasib, received orphan drug status from the FDA, boosting its stock and validating its oncology pipeline.

Eli Lilly, driven by metabolic treatments, saw revenue increase by 44.7% in FY 2025, while Pfizer's revenue slightly decreased by 1.6% as it focused on oncology acquisitions.

Eli Lilly and Company is investing an additional $870 million in Gate Bioscience to develop a new class of small-molecule drugs targeting difficult-to-drug extracellular proteins.

Eli Lilly announced positive phase 2 trial results for EloraTZP, a new combination weight loss drug, demonstrating greater efficacy than existing treatments and advancing to phase 3 trials in Q4 2026.

Eli Lilly is entering the aesthetics market, seeking to acquire drugs for skin, body, and hair conditions.

Eli Lilly's stock is rated a high-confidence buy, with a target price of $1,401.42, driven by strong Q2 earnings, pipeline advancements including retatrutide, and significant revenue growth despite price pressures.

Eli Lilly's $3 billion pharmaceutical plant in Katwijk, Netherlands, received permit approval to manufacture diabetes and weight-loss medicines.

Eli Lilly is adopting a direct-to-consumer sales model in Australia, while Novartis has acquired an experimental mRNA therapy from a Chinese firm, and NIH research grant funding is facing transparency issues.

Eli Lilly's new data reveal its strong commitment to developing next-generation weight-loss drugs to address obesity.